Terms ending in 2027
Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,053,556 | GLYPICAN-3 (GPC3)-Derived Tumor Rejection Antigenic Peptides Useful for HLA-A2-POSITIVE Patients and Pharmaceutical Comprising the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,545,437 | Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides In force · Medium confidence | Oncotherapy Science, Inc. | In force | Medium confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.